Genmab A/S (GMAB) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab A/S (GMABResearch Report) today and set a price target of $24. The company’s shares closed last Monday at $19.89.

Selvaraju observed:

“We used a discounted cash flow (DCF)-based approach to valuing 2.0% terminal growth rate, 8% discount rate and 23% effective tax rate. We assign a 90% probability of launch to DARZALEX in smoldering MM; a 75% probability of launch to ARZERRA in RR-MS; an 85% probability of launch to teprotumumab; and a 45% probability to tisotumab vedotin for cervical cancer.”

According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.3% and a 32.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Stealth Biotherapeutics Corp.

Currently, the analyst consensus on Genmab A/S is a Strong Buy with an average price target of $23.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $21.45 and a one-year low of $12.10. Currently, Genmab A/S has an average volume of 406.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases.